Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints
Authors:
Open Access
- 14 December 2024
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (8) , 1408-1417.e4
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (1U01DK134321)
This publication has 46 references indexed in Scilit:
- Navigating the complexities of drug development for inflammatory bowel diseaseNature Reviews Drug Discovery, 2024
- International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel diseaseNature Reviews Gastroenterology & Hepatology, 2021
- Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control studyThe Lancet Gastroenterology & Hepatology, 2021
- Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2020
- Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug DevelopmentClinical Gastroenterology and Hepatology, 2019
- The pattern and outcome of acute severe colitisJournal of Crohn's and Colitis, 2010
- Delayed surgery for acute severe colitis is associated with increased risk of postoperative complicationsBritish Journal of Surgery, 2010
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Stratified Randomization for Clinical TrialsJournal of Clinical Epidemiology, 1999
- Preliminary report: cyclosporin in treatment of severe active ulcerative colitisThe Lancet, 1990